Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2011

01-07-2011 | Epidemiology

BRCA1 and BRCA2 germline mutations in Uruguayan breast and breast–ovarian cancer families. Identification of novel mutations and unclassified variants

Authors: L. Delgado, G. Fernández, G. Grotiuz, S. Cataldi, A. González, N. LLuveras, M. Heguaburu, R. Fresco, D. Lens, G. Sabini, I. M. Muse

Published in: Breast Cancer Research and Treatment | Issue 1/2011

Login to get access

Abstract

The aim of the present study was to analyze BRCA1 and BRCA2 mutations in Uruguayan families with breast and breast/ovarian cancer. Probands from 42 families with at least three cases of female breast cancer (BC) or two cases and subcriteria (paternal transmission, ovarian cancer, bilateral BC, male BC, Ashkenazi Jewish ancestry) in the same lineage, at least one diagnosed before age 50, were screened for germline mutations. PCR amplification of all exons and intron–exon boundaries were performed, followed by protein truncation test, heteroduplex analysis, and direct sequencing. We identified seven different truncating mutations in seven families, five in BRCA2 (three in site-specific BC families and two in breast–ovarian cancer families) and two in BRCA1 (one in a site-specific BC family and the other in a breast–ovarian cancer family). Both BRCA1 mutations (5583insT and 2687T>G) and one of the five BRCA2 mutations (3829insTdel35) were not previously reported. We also detected ten sequence variants of unknown significance, five of them not described before. The low frequency of BRCA1/2 mutations (0.17) is in agreement with that reported in studies which included families with similar selection criteria. However, the observed predominance of BRCA2 (0.12) over BRCA1 mutations (0.05) is in contrast with the higher proportion of BRCA1 mutations communicated for most previous studies, even those with a predominance of site-specific BC families. Meanwhile, it has been described in one Chilean and some Spanish and Italian reports, highlighting the strong dependence between the mutational spectra and the ethnicity of the population analyzed.
Literature
1.
go back to reference Vasallo JA, De Stefani E, Barrios E, Ronco A (2001) II Atlas de incidencia del cáncer en Uruguay 1996–1997. CHLCC, Montevideo Vasallo JA, De Stefani E, Barrios E, Ronco A (2001) II Atlas de incidencia del cáncer en Uruguay 1996–1997. CHLCC, Montevideo
2.
go back to reference Vasallo JA, Barrios E (1999) III Atlas de mortalidad por cáncer en el Uruguay. Comparación de 2 quinquenios 1994–1998 y 1999–2003. CHLCC, Montevideo Vasallo JA, Barrios E (1999) III Atlas de mortalidad por cáncer en el Uruguay. Comparación de 2 quinquenios 1994–1998 y 1999–2003. CHLCC, Montevideo
3.
go back to reference Arver B, Quan Du, Chen J, Luo L, Lindblon A (2000) Hereditary breast cancer: a review. Cancer Biol 10:271–288CrossRef Arver B, Quan Du, Chen J, Luo L, Lindblon A (2000) Hereditary breast cancer: a review. Cancer Biol 10:271–288CrossRef
4.
go back to reference Lux MP, Fasching PA, Beckmann MW (2006) Hereditary breast and ovarian cancer: review and future perspectives. J Mol Med 85:16–28CrossRef Lux MP, Fasching PA, Beckmann MW (2006) Hereditary breast and ovarian cancer: review and future perspectives. J Mol Med 85:16–28CrossRef
5.
go back to reference Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A, Sholnick MH (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71PubMedCrossRef Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A, Sholnick MH (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71PubMedCrossRef
6.
go back to reference Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G, Barfoot R, Hamoudi R, Patel S, Rice C, Biggs P, Hashim Y, Smith A, Connor F, Arason A, Gudmundsson J, Ficenec D, Keisell D, Ford D, Tonin P, Biship DT, Spurr NK, Ponder BAJ, Eeles R, Peto J, Devilee P, Cornelisse C, Lynch H, Narod S, Lenoir G, Egilsson V, Barkadottir RB, Easton DF, Bentley DR, Futreal PA, Ashworth A, Stratton MR (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789–792PubMedCrossRef Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G, Barfoot R, Hamoudi R, Patel S, Rice C, Biggs P, Hashim Y, Smith A, Connor F, Arason A, Gudmundsson J, Ficenec D, Keisell D, Ford D, Tonin P, Biship DT, Spurr NK, Ponder BAJ, Eeles R, Peto J, Devilee P, Cornelisse C, Lynch H, Narod S, Lenoir G, Egilsson V, Barkadottir RB, Easton DF, Bentley DR, Futreal PA, Ashworth A, Stratton MR (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789–792PubMedCrossRef
8.
go back to reference Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpper KL, Scholl T, Tavtigian SV, Pruss DR, Critchfield GC (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10, 000 individuals. J Clin Oncol 20(6):1480–1490PubMedCrossRef Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpper KL, Scholl T, Tavtigian SV, Pruss DR, Critchfield GC (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10, 000 individuals. J Clin Oncol 20(6):1480–1490PubMedCrossRef
9.
go back to reference Ferla R, Calò V, Cascio S, Rinaldi G, Badalamenti G, Carreca I, Surmacz E, Colucci G, Bazan V, Russo A (2007) Founder mutations in BRCA1 and BRCA2 genes. Ann Oncol 18(Suppl 6):vi 93–vi 98 Ferla R, Calò V, Cascio S, Rinaldi G, Badalamenti G, Carreca I, Surmacz E, Colucci G, Bazan V, Russo A (2007) Founder mutations in BRCA1 and BRCA2 genes. Ann Oncol 18(Suppl 6):vi 93–vi 98
10.
go back to reference Szabo CI, King MC (1997) Population genetics of BRCA1 and BRCA2. Am J Hum Genet 60:1013–1020PubMed Szabo CI, King MC (1997) Population genetics of BRCA1 and BRCA2. Am J Hum Genet 60:1013–1020PubMed
11.
go back to reference Neuhausen SL (1999) Ethnic differences in cancer risk resulting from genetic variation. Cancer 86(11 Suppl):2575–2582PubMedCrossRef Neuhausen SL (1999) Ethnic differences in cancer risk resulting from genetic variation. Cancer 86(11 Suppl):2575–2582PubMedCrossRef
12.
go back to reference Metcalfe KA, Poll A, Royer R, Llacuachaqui M, Tulman A, Sun P, Narod SA (2010) Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J Clin Oncol 28(3):387–391PubMedCrossRef Metcalfe KA, Poll A, Royer R, Llacuachaqui M, Tulman A, Sun P, Narod SA (2010) Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J Clin Oncol 28(3):387–391PubMedCrossRef
13.
go back to reference Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Heching N, Peretz T (1997) The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 60(3):505–514PubMed Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Heching N, Peretz T (1997) The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 60(3):505–514PubMed
14.
go back to reference Sans M, Salzano FM, Chakraborty R (1997) Historical genetics in Uruguay: estimates of biological origins and their problems. Hum Biol 69(2):161–170PubMed Sans M, Salzano FM, Chakraborty R (1997) Historical genetics in Uruguay: estimates of biological origins and their problems. Hum Biol 69(2):161–170PubMed
15.
go back to reference Gascue C, Mimbacas A, Sans M, Gallino JP, Bertoni B, Hidalgo P, Cardoso H (2005) Frequencies of the four major Amerindian mtDNA haplogroups in the population of Montevideo, Uruguay. Hum Biol 77(6):873–878PubMedCrossRef Gascue C, Mimbacas A, Sans M, Gallino JP, Bertoni B, Hidalgo P, Cardoso H (2005) Frequencies of the four major Amerindian mtDNA haplogroups in the population of Montevideo, Uruguay. Hum Biol 77(6):873–878PubMedCrossRef
16.
go back to reference Ruiz-Flores P, Sinilnikova OM, Badzioch M, Calderón-Garcidueñas AL, Chopin S, Fabrice JF, González-Guerrero JF, Szabo C, Lenoir G, Goldgar D, Barrera-Saldaña H (2002) BRCA1 and BRCA2 mutation analysis of early-onset and familial breast cancer cases in Mexico. Hum Mutat 20:474–475PubMedCrossRef Ruiz-Flores P, Sinilnikova OM, Badzioch M, Calderón-Garcidueñas AL, Chopin S, Fabrice JF, González-Guerrero JF, Szabo C, Lenoir G, Goldgar D, Barrera-Saldaña H (2002) BRCA1 and BRCA2 mutation analysis of early-onset and familial breast cancer cases in Mexico. Hum Mutat 20:474–475PubMedCrossRef
17.
go back to reference Jara L, Ampuero S, Santibáñez E, Seccia L, Rodríguez J, Bustamante M, Martínez V, Catenaccio A, Lay-Son G, Blanco R, Reyes JM (2006) BRCA1 and BRCA2 mutations in a South American population. Cancer Genet Cytogenet 166(1):36–45PubMedCrossRef Jara L, Ampuero S, Santibáñez E, Seccia L, Rodríguez J, Bustamante M, Martínez V, Catenaccio A, Lay-Son G, Blanco R, Reyes JM (2006) BRCA1 and BRCA2 mutations in a South American population. Cancer Genet Cytogenet 166(1):36–45PubMedCrossRef
18.
go back to reference Gallardo M, Silva A, Rubio L, Alvarez C, Torrealba C, Salinas M, Tapia T, Faundez P, Palma L, Riccio ME, Paredes H, Rodriguez M, Cruz A, Rousseau R, King MC, Camus M, Alvarez M, Carvallo P (2006) Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype–phenotype correlations. Breast Cancer Res Treat 95:81–87PubMedCrossRef Gallardo M, Silva A, Rubio L, Alvarez C, Torrealba C, Salinas M, Tapia T, Faundez P, Palma L, Riccio ME, Paredes H, Rodriguez M, Cruz A, Rousseau R, King MC, Camus M, Alvarez M, Carvallo P (2006) Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype–phenotype correlations. Breast Cancer Res Treat 95:81–87PubMedCrossRef
19.
go back to reference Gomes MC, Costa MM, Borojevic R, Monteiro AN, Vieira R, Koifman S, Koifman RJ, Li S, Royer R, Zhang S, Narod SA (2007) Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil. Breast Cancer Res Treat 103(3):349–353PubMedCrossRef Gomes MC, Costa MM, Borojevic R, Monteiro AN, Vieira R, Koifman S, Koifman RJ, Li S, Royer R, Zhang S, Narod SA (2007) Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil. Breast Cancer Res Treat 103(3):349–353PubMedCrossRef
20.
go back to reference Vidal-Millán S, Taja-Chayeb L, Gutiérrez-Hernández O, Ramírez Ugalde MT, Robles-Vidal C, Bargallo-Rocha E, Mohar-Betancourt A, Dueñas-González A (2009) Mutational analysis of BRCA1 and BRCA2 genes in Mexican breast cancer patients. Eur J Gynaecol Oncol 30(5):527–530PubMed Vidal-Millán S, Taja-Chayeb L, Gutiérrez-Hernández O, Ramírez Ugalde MT, Robles-Vidal C, Bargallo-Rocha E, Mohar-Betancourt A, Dueñas-González A (2009) Mutational analysis of BRCA1 and BRCA2 genes in Mexican breast cancer patients. Eur J Gynaecol Oncol 30(5):527–530PubMed
21.
go back to reference Schubert EL, Lee MK, Mefford HC, Argonza RH, Morrow JE, Hull J, Dann JL, King MC (1997) BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2. Am J Hum Genet 60:1031–1040PubMed Schubert EL, Lee MK, Mefford HC, Argonza RH, Morrow JE, Hull J, Dann JL, King MC (1997) BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2. Am J Hum Genet 60:1031–1040PubMed
22.
go back to reference Mullineax LG, Castellano TM, Shaw J, Axell L, Wood ME, Diab S, Klein C, Sitarik M, Deffenbaugh AM, Graw SL (2003) Identification of germline 185delAG BRCA1 mutations in non-Jewish Americans of Spanish ancestry from the San Luis Valley, Colorado. Cancer 98:597–602CrossRef Mullineax LG, Castellano TM, Shaw J, Axell L, Wood ME, Diab S, Klein C, Sitarik M, Deffenbaugh AM, Graw SL (2003) Identification of germline 185delAG BRCA1 mutations in non-Jewish Americans of Spanish ancestry from the San Luis Valley, Colorado. Cancer 98:597–602CrossRef
23.
go back to reference Vogel KJ, Atchley DP, Erlichman J, Broglio KR, Ready KJ, Valero V, Amos CI, Hortobagyi GN, Lu KH, Arun B (2007) BRCA1 and BRCA2 genetic testing in hispanic patients: mutation prevalence and evaluation of the BRCAPRO. Risk Assess Model J Clin Oncol 25:4635–4641 Vogel KJ, Atchley DP, Erlichman J, Broglio KR, Ready KJ, Valero V, Amos CI, Hortobagyi GN, Lu KH, Arun B (2007) BRCA1 and BRCA2 genetic testing in hispanic patients: mutation prevalence and evaluation of the BRCAPRO. Risk Assess Model J Clin Oncol 25:4635–4641
24.
go back to reference Li FP, Fraumeni JF Jr, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW (1998) A cancer family syndrome in twenty-four kindreds. Cancer Res 48:5358–5362 Li FP, Fraumeni JF Jr, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW (1998) A cancer family syndrome in twenty-four kindreds. Cancer Res 48:5358–5362
25.
go back to reference Delgado L, Fernández G, González A, Bressac-de Paillerets B, Gualco G, Bombled J, Cataldi S, Sabini G, Roca R, Musé IM (2002) Hereditary breast cancer associated with a germline BRCA2 mutation in identical female twins with similar disease expression. Cancer Genet Cytogenet 133(1):24–28PubMedCrossRef Delgado L, Fernández G, González A, Bressac-de Paillerets B, Gualco G, Bombled J, Cataldi S, Sabini G, Roca R, Musé IM (2002) Hereditary breast cancer associated with a germline BRCA2 mutation in identical female twins with similar disease expression. Cancer Genet Cytogenet 133(1):24–28PubMedCrossRef
26.
go back to reference Hogervorst FB, Cornelis RS, Bout M, van Vliet M, Oosterwijk JC, Olmer R, Bakker B, Klijn JG, Vasen HF, Meijers-Heijboer H, Menko F, Cornelisse C, Dunnen J, Devilee P, Ommen G-J (1995) Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet 10(2):208–212PubMedCrossRef Hogervorst FB, Cornelis RS, Bout M, van Vliet M, Oosterwijk JC, Olmer R, Bakker B, Klijn JG, Vasen HF, Meijers-Heijboer H, Menko F, Cornelisse C, Dunnen J, Devilee P, Ommen G-J (1995) Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet 10(2):208–212PubMedCrossRef
27.
go back to reference Serova OM, Mazoyer S, Puget N, Dubois V, Tonin P, Shugart YY, Goldgar D, Narod SA, Lynch HT, Lenoir GM (1997) Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes? Am J Hum Genet 60(3):486–495PubMed Serova OM, Mazoyer S, Puget N, Dubois V, Tonin P, Shugart YY, Goldgar D, Narod SA, Lynch HT, Lenoir GM (1997) Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes? Am J Hum Genet 60(3):486–495PubMed
28.
go back to reference Verhoog LC, van den Ouweland AM, Berns E, van Veghel-Plandsoen MM, van Staveren IL, Wagner A, Bartels CC, Tilanus-Linthorst MM, Devilee P, Seynaeve C, Halley DJ, Niermeijer MF, Klijn JG, Meijers-Heijboer H (2001) Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families. Eur J Cancer 37(16):2082–2090PubMedCrossRef Verhoog LC, van den Ouweland AM, Berns E, van Veghel-Plandsoen MM, van Staveren IL, Wagner A, Bartels CC, Tilanus-Linthorst MM, Devilee P, Seynaeve C, Halley DJ, Niermeijer MF, Klijn JG, Meijers-Heijboer H (2001) Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families. Eur J Cancer 37(16):2082–2090PubMedCrossRef
29.
go back to reference Milner J, Ponder B, Hughes-Davies L, Seltmann M, Kouzarides T (1997) Transcriptional activation functions in BRCA2. Nature 386:772–773PubMedCrossRef Milner J, Ponder B, Hughes-Davies L, Seltmann M, Kouzarides T (1997) Transcriptional activation functions in BRCA2. Nature 386:772–773PubMedCrossRef
30.
go back to reference Liede A, Karlan BY, Narod SA (2004) Cancer risks for male carriers of germlinemutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 22(4):735–742PubMedCrossRef Liede A, Karlan BY, Narod SA (2004) Cancer risks for male carriers of germlinemutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 22(4):735–742PubMedCrossRef
31.
go back to reference Liede A, Levy-Lahad E, Friedman E (2007) Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer 96(1):11–15CrossRef Liede A, Levy-Lahad E, Friedman E (2007) Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer 96(1):11–15CrossRef
32.
go back to reference Díez O, Cortés J, Domènech M, Brunet J, Del Río E, Pericay C, Sanz J, Alonso C, Baiget M (1999) BRCA1 mutation analysis in 83 Spanish breast and breast/ovarian cancer families. Int J Cancer 83(4):465–469PubMedCrossRef Díez O, Cortés J, Domènech M, Brunet J, Del Río E, Pericay C, Sanz J, Alonso C, Baiget M (1999) BRCA1 mutation analysis in 83 Spanish breast and breast/ovarian cancer families. Int J Cancer 83(4):465–469PubMedCrossRef
33.
go back to reference De la Hoya M, Osorio A, Godino J, Sulleiro S, Tosar A, Perez-Segura P, Fernandez C, Rodríguez R, Díaz-Rubio E, Benítez J, Devilee P, Caldés T (2002) Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing. Int J Cancer 97(4):466–471CrossRef De la Hoya M, Osorio A, Godino J, Sulleiro S, Tosar A, Perez-Segura P, Fernandez C, Rodríguez R, Díaz-Rubio E, Benítez J, Devilee P, Caldés T (2002) Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing. Int J Cancer 97(4):466–471CrossRef
34.
go back to reference Ottini L, D’Amico C, Noviello C, Lauro S, Lalle M, Fornarini G, Colantuoni OA, Pizzi C, Cortesi E, Carlini S, Guadagni F, Bianco AR, Frati L, Contegiacomo A, Mariani-Costantini R (2000) BRCA1 and BRCA2 mutations in central and southern Italian patients. Breast Cancer Res 2(4):307–310PubMedCrossRef Ottini L, D’Amico C, Noviello C, Lauro S, Lalle M, Fornarini G, Colantuoni OA, Pizzi C, Cortesi E, Carlini S, Guadagni F, Bianco AR, Frati L, Contegiacomo A, Mariani-Costantini R (2000) BRCA1 and BRCA2 mutations in central and southern Italian patients. Breast Cancer Res 2(4):307–310PubMedCrossRef
35.
go back to reference Turchetti D, Cortesi L, Federico M, Bertoni C, Mangone L, Ferrari S, Silingardi V (2000) BRCA1 mutations and clinicopathological features in a sample of Italian women with early-onset breast cancer. Eur J Cancer 36(16):2083–2089PubMedCrossRef Turchetti D, Cortesi L, Federico M, Bertoni C, Mangone L, Ferrari S, Silingardi V (2000) BRCA1 mutations and clinicopathological features in a sample of Italian women with early-onset breast cancer. Eur J Cancer 36(16):2083–2089PubMedCrossRef
36.
go back to reference Santarosa M, Viel A, Dolcetti R, Crivellari D, Magri MD, Pizzichetta MA, Tibiletti MG, Gallo A, Tumolo S, Del Tin L, Boiocchi M (1998) Low incidence of BRCA1 mutations among Italian families with breast and ovarian cancer. Int J Cancer 78(5):581–586PubMedCrossRef Santarosa M, Viel A, Dolcetti R, Crivellari D, Magri MD, Pizzichetta MA, Tibiletti MG, Gallo A, Tumolo S, Del Tin L, Boiocchi M (1998) Low incidence of BRCA1 mutations among Italian families with breast and ovarian cancer. Int J Cancer 78(5):581–586PubMedCrossRef
37.
go back to reference Santarosa M, Dolcetti R, Magri MD, Crivellari D, Tibiletti MG, Gallo A, Tumolo S, Della Puppa L, Furlan D, Boiocchi M, Viel A (1999) BRCA1 and BRCA2 genes: role in hereditary breast and ovarian cancer in Italy. Int J Cancer 83(1):5–9PubMedCrossRef Santarosa M, Dolcetti R, Magri MD, Crivellari D, Tibiletti MG, Gallo A, Tumolo S, Della Puppa L, Furlan D, Boiocchi M, Viel A (1999) BRCA1 and BRCA2 genes: role in hereditary breast and ovarian cancer in Italy. Int J Cancer 83(1):5–9PubMedCrossRef
38.
go back to reference Osorio A, Barroso A, Martínez B, Cebrián A, San Román JM, Lobo F, Robledo M, Benítez J (2000) Molecular analysis of the BRCA1 and BRCA2 genes in 32 breast and/or ovarian cancer Spanish families. Br J Cancer 82(7):1266–1270PubMedCrossRef Osorio A, Barroso A, Martínez B, Cebrián A, San Román JM, Lobo F, Robledo M, Benítez J (2000) Molecular analysis of the BRCA1 and BRCA2 genes in 32 breast and/or ovarian cancer Spanish families. Br J Cancer 82(7):1266–1270PubMedCrossRef
39.
go back to reference Díez O, Osorio A, Durán M, Martinez-Ferrandis JI, de la Hoya M, Salazar R, Vega A, Campos B, Rodríguez-López R, Velasco E, Chaves J, Díaz-Rubio E, Jesús Cruz J, Torres M, Esteban E, Cervantes A, Alonso C, San Román JM, González-Sarmiento R, Miner C, Carracedo A, Eugenia Armengod M, Caldés T, Benítez J, Baiget M (2003) Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian câncer patients: a high proportion of mutations unique to Spain and evidence of founder effects. Hum Mutat 22(4):301–312PubMedCrossRef Díez O, Osorio A, Durán M, Martinez-Ferrandis JI, de la Hoya M, Salazar R, Vega A, Campos B, Rodríguez-López R, Velasco E, Chaves J, Díaz-Rubio E, Jesús Cruz J, Torres M, Esteban E, Cervantes A, Alonso C, San Román JM, González-Sarmiento R, Miner C, Carracedo A, Eugenia Armengod M, Caldés T, Benítez J, Baiget M (2003) Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian câncer patients: a high proportion of mutations unique to Spain and evidence of founder effects. Hum Mutat 22(4):301–312PubMedCrossRef
Metadata
Title
BRCA1 and BRCA2 germline mutations in Uruguayan breast and breast–ovarian cancer families. Identification of novel mutations and unclassified variants
Authors
L. Delgado
G. Fernández
G. Grotiuz
S. Cataldi
A. González
N. LLuveras
M. Heguaburu
R. Fresco
D. Lens
G. Sabini
I. M. Muse
Publication date
01-07-2011
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-010-1320-2

Other articles of this Issue 1/2011

Breast Cancer Research and Treatment 1/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine